Consider the independent Wishart matrices \(S_{1} \sim W\left(\Sigma+\lambda \theta, q_{1}\right)\) and \(S_{2} \sim\) \(W\left(\Sigma, q_{2}\right)\), where \(\Sigma\) is an unknown positive definite (p.d.) matrix, \(\theta\) is an unknown nonnegative definite (n.n.d.) matrix, and \(\lambda\) is a
Asymptotic Properties of the Estimators for Multivariate Components of Variance
β Scribed by S. Remadi; Y. Amemiya
- Publisher
- Elsevier Science
- Year
- 1994
- Tongue
- English
- Weight
- 736 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0047-259X
No coin nor oath required. For personal study only.
β¦ Synopsis
Estimation of the covariance matrices in the multivariate balanced one-way random effect model is discussed. The rank of the between-group covariance matrix plays a large role in model building as well as in assessing asymptotic properties of the estimated covariance matrices. The restricted (residual) maximum likelihood estimators derived under a rank condition are considered. Asymptotic properties of the estimators are derived for a possibly incorrectly specified rank and under either the number of groups, the number of replicates, or both, tending to infinity. A higher order expansion covering various cases leads to a common approximate inference procedure which can be used in a wide range of practical situations. A simulation study is also presented. 1994 Academic Press. Inc.
π SIMILAR VOLUMES
In order to construct confidence sets for a marginal density f of a strictly stationary continuous time process observed over the time interval [0, T ], it is necessary to have at one's disposal a Central Limit Theorem for the kernel density estimator f T . In this paper we address the question of n
A multivariate point process is a random jump measure in time and space. Its distribution is determined by the compensator of the jump measure. By an empirical estimator we understand a linear functional of the jump measure. We give conditions for a nonparametric version of local asymptotic normalit
Characteristics of the variance component for the subject-by-formulation interaction ( 2 D ), estimated in simulated studies of individual bioequivalence and in three-and four-period cross-over trials reported by the FDA, were compared. 2 D was estimated by (i) restricted maximum likelihood (REML) a